Primary Hepatic Squamous Cell Carcinoma With High Microsatellite Instability Shows Good Response to Programmed Cell Death 1 Inhibitor as Adjuvant Therapy
Autor: | Hui Zhi Zhang, Chun Nian Wang, Yang Ke Hu, Sheng Dong Wu, Ding Zhang, Ke Wang, Jian Nan Sun, Guo Gao, Cai De Lu |
---|---|
Rok vydání: | 2021 |
Předmět: |
Male
0301 basic medicine Cirrhosis Programmed Cell Death 1 Receptor Disease Antibodies Monoclonal Humanized Disease-Free Survival 03 medical and health sciences 0302 clinical medicine Programmed cell death 1 medicine Adjuvant therapy Hepatectomy Humans Basal cell Immune Checkpoint Inhibitors Aged Hepatology biology business.industry Liver Neoplasms Microsatellite instability medicine.disease 030104 developmental biology Chemotherapy Adjuvant Carcinoma Squamous Cell biology.protein Cancer research Microsatellite Instability 030211 gastroenterology & hepatology Hepatic Cyst Liver cancer business |
Zdroj: | Hepatology. 74:1695-1697 |
ISSN: | 1527-3350 0270-9139 |
DOI: | 10.1002/hep.31737 |
Popis: | Primary hepatic squamous cell carcinoma (SCC) is a rare, highly aggressive liver cancer that is associated with intrahepatic stone, liver cirrhosis, hepatic cyst, and Caroli's disease. At present, there are no settled therapy guidelines for primary hepatic SCC. Patients with successful surgical resection have a tumor-free survival of approximately 6 to 9 months.(1,2) Immune checkpoint inhibitors (ICIs) are a promising treatment for multiple tumor types, with significant efficacy and manageable toxicity.(3). |
Databáze: | OpenAIRE |
Externí odkaz: |
načítá se...